# CBA Versus FBA Conditioning Followed by Haploidentical Allogeneic HSCT in Treatment of High Risk and Refractory AML

> **NCT03384225** · PHASE3 · UNKNOWN · sponsor: **Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine** · enrollment: 120 (estimated)

## Conditions studied

- High Risk Acute Myeloid Leukemia
- Allogeneic Hematopoeitic Stem Cell Transplantation

## Interventions

- **DRUG:** Cladribine
- **DRUG:** Fludarabine
- **DRUG:** Busulfan
- **DRUG:** Cytarabine

## Key facts

- **NCT ID:** NCT03384225
- **Lead sponsor:** Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2016-08-01
- **Primary completion:** 2022-07-31
- **Final completion:** 2022-07-31
- **Target enrollment:** 120 (ESTIMATED)
- **Last updated:** 2021-10-12

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03384225

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03384225, "CBA Versus FBA Conditioning Followed by Haploidentical Allogeneic HSCT in Treatment of High Risk and Refractory AML". Retrieved via AI Analytics 2026-07-09 from https://api.ai-analytics.org/clinical/NCT03384225. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*